Orion Corporation’s financial reporting and Annual General Meeting in 2023
ORION CORPORATION
STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR
15 JULY 2022 at 11.00 EEST
Orion Corporation’s financial reporting and Annual General Meeting in 2023
Orion Corporation will publish its Financial Statement Release 2022 on Thursday, 9 February 2023.
The publication dates of the Interim Reports and the Half-Year Financial Report in 2023 are as follows:
| Interim Report January-March 2023 Half-Year Financial Report January-June 2023 Interim Report January-September 2023 |
Thursday, 27 April 2023 Monday, 17 July 2023 Thursday, 26 October 2023 |
The Financial Statements and the Report of the Board of Directors for 2022 will be published on the Company’s website at the latest in week 9/2023.
The Annual General Meeting is planned to be held on Wednesday, 22 March 2023.
Orion’s financial reports and related presentation material are available on the Group’s website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion’s mailing lists for releases.
Orion Corporation
| Timo Lappalainen
President and CEO |
Olli Huotari
SVP, Corporate Functions |
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are oncology and pain. Orion’s net sales in 2021 amounted to EUR 1,041 million and the company had about 3,350 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.
